Trial intelligence / Profile preview

Proof-of-concept multiple intra-articular LNA043 injections for cartilage regeneration in knee articular cartilage lesions

2016-004052-30Phase 2Completed

Sponsor
Novartis
Start
Mar 2017
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in chondral knee defect, knee osteoarthritis (OA) and Traumatic cartilage degeneration comparing LNA043 intra-articular injections with Placebo intra-articular injections (2 arms). Primary endpoint: Articular cartilage bilayer collagen organisation evaluated with T2. Started Mar 2017; status: completed.

02

Drugs

LNA043
03

Conditions

chondral knee defectknee osteoarthritis (OA)Traumatic cartilage degeneration

Beyond the preview

Go deeper on 2016-004052-30.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2016-004052-30.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call